Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Takeda Pharmaceutical Company (0A87) Share Price & Analysis

0A87 Stock Chart & Stats

$21.12$0.62(3.01%)
At close: 12:00 AM GMT
$18$18.5$19$19.524 Sep5 Oct19 Oct
Day’s Range
$21.12 - $21.12
52-Week Range
$13.47 - $21.12
Previous Close
$20.50
Volume
N/A
Average Volume (3M)
100
Market Cap
$67.24B
Enterprise Value
$85.30B
Total Cash (Recent Filing)
$454.40B
Total Debt (Recent Filing)
$4.58T
Price to Earnings (P/E)
27.1
Beta
0.41
Next Earnings
Jan 28, 2027 (Est.)
EPS Estimate
0.28
Next Dividend Ex-Date
N/A
Dividend Yield
3.29%

Bulls Say, Bears Say

Bulls Say

Strong Revenue And Operating Profitability

Takeda combines sustained multi-year revenue growth with strong gross and operating profitability, indicating a substantial commercial base across its therapeutic franchises. These economics can support continued research investment, product launches, and resilience as individual medicines mature.

Expanding New-Product Pipeline

Rapid growth from recently launched products provides an avenue to replace aging medicines and diversify Takeda’s revenue base. Continued launches across narcolepsy, hematology and immunology could strengthen future growth if clinical, regulatory and commercial momentum persists.

Transformation Savings

A sizable, operationally tracked savings program can improve cost discipline and help fund research and commercial investment. Progress on procurement and the broader transformation may support operating profitability over the next several quarters, even while Takeda absorbs restructuring costs.

Bears Say

Mature Portfolio Revenue Pressure

Patent-related erosion and weakness in mature products create a continuing revenue replacement challenge rather than a temporary sales fluctuation. Takeda must scale newer medicines quickly enough to offset declining established brands, which can pressure growth and mix.

Weakening Cash-Flow Momentum

Positive cash generation remains an asset, but declining free cash flow and relatively light operating-cash conversion reduce financial predictability. Weaker cash momentum could constrain flexibility for acquisitions, pipeline investment, shareholder returns, or restructuring commitments.

Zasocitinib IBD Development Uncertainty

Uncertainty around dose response and the Phase III path weakens visibility for a potentially important pipeline asset. Additional data and development decisions may delay commercialization, increase investment needs, and leave future growth more dependent on other launches.

Takeda Pharmaceutical Company News

0A87 FAQ

What was Takeda Pharmaceutical Company’s price range in the past 12 months?
Takeda Pharmaceutical Company lowest share price was $13.47 and its highest was $21.12 in the past 12 months.
What is Takeda Pharmaceutical Company’s market cap?
Takeda Pharmaceutical Company’s market cap is $67.24B.
When is Takeda Pharmaceutical Company’s upcoming earnings report date?
Takeda Pharmaceutical Company’s next earnings report is estimated for Jan 28, 2027 (not yet confirmed), which is in 85 days.
How were Takeda Pharmaceutical Company’s earnings last quarter?
Takeda Pharmaceutical Company released its earnings results on Oct 29, 2026. The company reported $0.384 earnings per share for the quarter, beating the consensus estimate of $0.145 by $0.239.
Is Takeda Pharmaceutical Company overvalued?
According to Wall Street analysts Takeda Pharmaceutical Company’s price is currently Undervalued.
Does Takeda Pharmaceutical Company pay dividends?
Takeda Pharmaceutical Company does not currently pay dividends.
What is Takeda Pharmaceutical Company’s EPS estimate?
Takeda Pharmaceutical Company’s EPS estimate is 0.28.
How many shares outstanding does Takeda Pharmaceutical Company have?
Takeda Pharmaceutical Company has 3,204,437,000 shares outstanding.
What happened to Takeda Pharmaceutical Company’s price movement after its last earnings report?
Takeda Pharmaceutical Company reported an EPS of $0.384 in its last earnings report, beating expectations of $0.145. Following the earnings report the stock price went up 2.86%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Company?
Hedge funds hold Takeda Pharmaceutical Company shares: the largest hedge-fund position in Takeda Pharmaceutical Company is 1,205,609,072 shares, and hedge funds increased their holdings by 181.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology